Meredith K. Chuk

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab

Maitreyee Hazarika, Meredith K. Chuk, Marc R. Theoret et al. · Clinical Cancer Research · 2017 · 182 citations

Medicine, Pharmacology, Pharmacotherapy +17

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis

Julia A. Beaver, Maitreyee Hazarika, Flora Mulkey et al. · The Lancet Oncology · 2018 · 177 citations · Full text

Medicine, Dermatology, Oncology +17

Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma

Elizabeth Fox, Brigitte C. Widemann, Meredith K. Chuk et al. · Clinical Cancer Research · 2013 · 155 citations · Full text

Medicine, Oncology, Pharmacology +16

A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors

Elizabeth Fox, Richard Aplenc, Rochelle Bagatell et al. · Journal of Clinical Oncology · 2010 · 108 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma

Meredith K. Chuk, Jennie Chang, Marc R. Theoret et al. · Clinical Cancer Research · 2017 · 89 citations

Medicine, Oncology, Pharmacology +17